Company news
Jenkem Technology Co., Ltd. Class A (SSE:688356) news
Jenkem Technology Co., Ltd. Class A news releases on 6ix. Latest, Sep 9, 2026: "Jenkem Technology Co., Ltd."Announcement on Shareholding Reduction Plan…
Press releases & updates
"Jenkem Technology Co., Ltd."Announcement on Shareholding Reduction Plan of Director and Senior Management
September 8, 2026
"Jenkem Technology Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
August 31, 2026
"Jenkem Technology Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 25, 2026
"Jenkem Technology Co., Ltd."Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold and Result of Shareholding Reduction
August 24, 2026
"Jenkem Technology Co., Ltd."Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 5%
July 15, 2026
"Jenkem Technology Co., Ltd."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 14, 2026
"Jenkem Technology Co., Ltd."Announcement on the Investment and Construction of a New Project
June 30, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
June 23, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 22, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 25, 2026
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
May 11, 2026
Announcement on Renewing Engagement of Audit Institution for 2026
April 28, 2026
Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
April 16, 2026
Announcement on Pledge of Partial Shares by Shareholders with Over 5% of Shares
April 15, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 7, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
April 1, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Earnings Preannouncement for 2025
January 22, 2026
Announcement on Equity Change of Shareholder with Over 5% Shares Reaching 1% Scale and Result of Shareholding Reduction
January 5, 2026
Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 5%
December 8, 2025
2025年第二次临时股东会决议公告
November 18, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 1% Integer Multiple
November 17, 2025
Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
November 12, 2025
Shareholders' Inquiry Transfer Plan
November 11, 2025
Report for Q3 2025
October 30, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 17, 2025
Announcement on Change of Meeting Location for the 1st Extraordinary General Meeting in 2025
September 11, 2025
Announcement on Expiration of Independent Directors’ Re-election Term, the By-election of Independent Directors and the Adjustment of Members of the Special Committees of the Board of Directors
August 28, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 21, 2025
Announcement on Implementation of Dividend Distribution for 2024
July 6, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 10, 2025
Announcement on Voluntary Disclosure of Acceptance of Registration Application for Sodium Hyaluronate Compound Solution for Injection
May 28, 2025
Report for Q1 2025
April 28, 2025
Announcement on Voluntary Disclosure of Obtaining Medical Device Registration Certificate by Wholly-owned Subsidiary
April 25, 2025
Announcement on Convening Performance Meeting for 2024 and 1st Quarter of 2025
April 21, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Implementation Results of Share Repurchase and Share Changes
February 20, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
February 5, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Change of Employee Representative Supervisor and Chairman of the Board of Supervisors
November 27, 2024
Announcement on the Vesting Results of the 2nd Vesting Period of the Part Reserved for Grant under the 2021 Restricted Stock Incentive Plan and Listing of Shares
November 13, 2024
Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase II Clinical Trial of Pegylated Irinotecan in Treating Triple Negative Breast Cancer with Brain Metastasis
November 12, 2024
Announcement on Resolution of the 11th Meeting of the 3rd Board of Directors
November 8, 2024
Announcement on Correction of Report for Q3 2024
November 3, 2024
Announcement on Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital
October 30, 2024
Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase III Clinical Trial of Polyethylene Glycol Irinotecan for Treatment of Small Cell Lung Cancer
September 29, 2024
Announcement Published in a Journal Regarding Voluntary Disclosure of Phase II Study on the Safety, Tolerability and Preliminary Efficacy of Polyethylene Glycol Irinotecan as Second-Line Monotherapy for Small Cell Lung Cancer
September 4, 2024
Announcement on Meeting the Vesting Conditions in the 2nd Vesting Period of Those Reserved for Grant in the 2021 Restricted Stock Incentive Plan
August 29, 2024